Short Interest in Eterna Therapeutics Inc. (NASDAQ:ERNA) Expands By 427.1%

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 606,200 shares, an increase of 427.1% from the November 30th total of 115,000 shares. Currently, 1.2% of the company’s stock are short sold. Based on an average trading volume of 712,600 shares, the days-to-cover ratio is presently 0.9 days.

Eterna Therapeutics Price Performance

Shares of ERNA traded down $0.03 during mid-day trading on Friday, reaching $0.25. The company’s stock had a trading volume of 329,429 shares, compared to its average volume of 196,117. The company’s 50 day moving average is $0.64 and its 200 day moving average is $1.29. Eterna Therapeutics has a 12-month low of $0.22 and a 12-month high of $2.63. The stock has a market cap of $1.37 million, a PE ratio of -0.03 and a beta of 4.18.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.